Cubist Systematic Strategies LLC Sells 671 Shares of Chemed Co. (CHE)
Cubist Systematic Strategies LLC trimmed its stake in Chemed Co. (NYSE:CHE) by 38.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,059 shares of the company’s stock after selling 671 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Chemed were worth $214,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. APG Asset Management N.V. bought a new stake in Chemed in the third quarter valued at $5,657,000. Cabot Wealth Management Inc. lifted its stake in Chemed by 4.1% in the third quarter. Cabot Wealth Management Inc. now owns 18,062 shares of the company’s stock valued at $3,649,000 after buying an additional 715 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its stake in Chemed by 56.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 6,030 shares of the company’s stock valued at $1,218,000 after buying an additional 2,180 shares during the last quarter. Pinebridge Investments L.P. lifted its stake in Chemed by 66.6% in the second quarter. Pinebridge Investments L.P. now owns 3,544 shares of the company’s stock valued at $725,000 after buying an additional 1,417 shares during the last quarter. Finally, ClariVest Asset Management LLC lifted its stake in Chemed by 9.2% in the third quarter. ClariVest Asset Management LLC now owns 21,655 shares of the company’s stock valued at $4,375,000 after buying an additional 1,827 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.
Shares of Chemed Co. (NYSE:CHE) opened at $259.73 on Thursday. Chemed Co. has a one year low of $161.48 and a one year high of $261.91. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15. The firm has a market cap of $4,100.00, a PE ratio of 57.85, a P/E/G ratio of 2.87 and a beta of 1.16.
Chemed (NYSE:CHE) last issued its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.15. Chemed had a net margin of 8.49% and a return on equity of 30.54%. The business had revenue of $417.40 million for the quarter, compared to analysts’ expectations of $414.34 million. During the same period in the previous year, the business earned $1.73 earnings per share. The company’s revenue was up 6.3% on a year-over-year basis. research analysts predict that Chemed Co. will post 4.73 EPS for the current year.
In other Chemed news, Director Donald E. Saunders sold 500 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $227.75, for a total value of $113,875.00. Following the sale, the director now directly owns 10,298 shares in the company, valued at $2,345,369.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Patrick Williams sold 11,000 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $241.28, for a total transaction of $2,654,080.00. Following the completion of the sale, the insider now owns 74,857 shares in the company, valued at $18,061,496.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 45,679 shares of company stock worth $10,628,959. Company insiders own 4.90% of the company’s stock.
A number of equities research analysts have issued reports on CHE shares. Zacks Investment Research cut Chemed from a “buy” rating to a “hold” rating in a research note on Wednesday, September 13th. Royal Bank of Canada restated a “hold” rating and set a $209.00 price objective on shares of Chemed in a research note on Tuesday, October 3rd. KeyCorp restated a “hold” rating on shares of Chemed in a research note on Friday, October 27th. Oppenheimer lifted their price objective on shares of Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Finally, TheStreet upgraded shares of Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $236.00.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.